A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

← catalyst calendar

NCT06118411 · readout ≤ 590 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

614actual

Sites

148

Countries

Argentina, Belgium, Bulgaria +16

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-12-19

actual

When the study began enrolling

Primary completion

Mar 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2028

estimated

The whole study's end, after follow-up

First posted

2023-11-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-09

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Vitiligo

Interventions

Drug: Upadacitinib — also filed as ABT-494, Rinvoq
Drug: Placebo
Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

Primary outcomes

what the primary-completion date above is the date OF

Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline)

measured Week 48

Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (≥ 75% Improvement in F-VASI From Baseline)

measured Week 48

Percentage of Participants Achieving T-VASI 75 (≥ 75% Improvement in T-VASI From Baseline)

measured Study 4 Week 28

Number of Participants with Adverse Events (AEs)

measured Up to Approximately Week 175

Publications

PMID 42594914 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed